CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer

Tang,Shasha; Zhang,Yi; Lin,Xiaoyan; Wang,Hui; Yong,Liyun; Zhang,Hongyi; Cai,Fengfeng

doi:10.3892/ol.2022.13405

CLEC10A can serve as a potential therapeutic target and its level correlates with immune infiltration in breast cancer

Authors:
- Shasha Tang
- Yi Zhang
- Xiaoyan Lin
- Hui Wang
- Liyun Yong
- Hongyi Zhang
- Fengfeng Cai
View Affiliations

Affiliations: Department of Breast Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China, Department of Breast Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China, Laboratory of Tumor Molecular Biology, School of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China
Published online on: June 28, 2022 https://doi.org/10.3892/ol.2022.13405
Article Number: 285
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is one of the most common malignant cancers in females worldwide and greatly threatens women's health. The C‑type lectin domain family 10 member A (CLEC10A) is a member of the C‑type lectin receptor family that has been previously reported to promote the antitumor activity of immune cells. In the present study, the potential prognostic value of CLEC10A expression in BC was assessed using data from The Cancer Genome Atlas online database. Differences in the mRNA expression levels of CLEC10A between BC and normal tissues were then analyzed using the Tumor Immune Estimation Resource (TIMER) platform and the University of Alabama at Birmingham Cancer data analysis portal. Reverse transcription‑quantitative PCR was performed to validate the results of this analysis. The Kaplan‑Meier plotter database was used to evaluate the association between the mRNA expression levels of CLEC10A and clinical prognosis of BC. Based on the association between the mRNA expression levels of CLEC10A and the tumor immune microenvironment, the TIMER platform and the Tumor and Immune System Interaction Database website were utilized to assess the correlation between CLEC10A expression and the degree of tumor immune cell infiltration. The present study revealed that CLEC10A expression was significantly lower in BC tissues compared with that in normal tissues, which was in turn associated with poorer clinical outcomes. This suggested that lower CLEC10A expression levels were associated with unfavorable prognosis in BC. In addition, the expression level of CLEC10A was found to be positively associated with the level of different tumor‑infiltrating immune cells in BC, including CD8 T cells, B cells, macrophages and NK cells which, was in turn closely correlated with some gene markers such as CD19, CD8A, KIR2DS4 and PTGS2. These results suggest that the relationship between lower CLEC10A expression level and poor prognosis in BC may be due to the role of CLEC10A in the tumor immune microenvironment. In conclusion, CLEC10A may be a potential biomarker that can be used to efficiently predict prognosis in patients with BC.

View Figures

View References

1	Aushev VN, Lee E, Zhu J, Gopalakrishnan K, Li Q, Teitelbaum SL, Wetmur J, Degli Esposti D, Hernandez-Vargas H, Herceg Z, et al: Novel predictors of breast cancer survival derived from miRNA activity analysis. Clin Cancer Res. 24:581–591. 2018. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, et al: Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: A systematic review and meta-analysis. Lancet Oncol. 20:361–370. 2019. View Article : Google Scholar
4	Shachar SS, Deal AM, Weinberg M, Williams GR, Nyrop KA, Popuri K, Choi SK and Muss HB: Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res. 23:3537–3543. 2017. View Article : Google Scholar : PubMed/NCBI
5	Lischka A, Doberstein N, Freitag-Wolf S, Kocak A, Gemoll T, Heselmeyer-Haddad K, Ried T, Auer G and Habermann JK: Genome instability profiles predict disease outcome in a cohort of 4,003 patients with breast cancer. Clin Cancer Res. 26:4606–4615. 2020. View Article : Google Scholar : PubMed/NCBI
6	Abu-Thuraia A, Goyette MA, Boulais J, Delliaux C, Apcher C, Schott C, Chidiac R, Bagci H, Thibault MP, Davidson D, et al: AXL confers cell migration and invasion by hijacking a PEAK1-regulated focal adhesion protein network. Nat Commun. 11:35862020. View Article : Google Scholar : PubMed/NCBI
7	Pirro M, Mohammed Y, van Vliet SJ, Rombouts Y, Sciacca A, de Ru AH, Janssen GMC, Tjokrodirijo RTN, Wuhrer M, van Veelen PA and Hensbergen PJ: N-Glycoproteins have a major role in MGL binding to colorectal cancer cell lines: Associations with overall proteome diversity. Int J Mol Sci. 21:55222020. View Article : Google Scholar
8	Eggink LL, Roby KF, Cote R and Kenneth Hoober J: An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides. J Immunother Cancer. 6:282018. View Article : Google Scholar : PubMed/NCBI
9	Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ and Fox BA: Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40. Clin Cancer Res. 23:6165–6177. 2017. View Article : Google Scholar : PubMed/NCBI
10	Heger L, Balk S, Luhr JJ, Heidkamp GF, Lehmann CH, Hatscher L, Purbojo A, Hartmann A, Garcia-Martin F, Nishimura SI, et al: CLEC10A is a specific marker for human CD1c⁺ dendritic cells and enhances their toll-like receptor 7/8-induced cytokine secretion. Front Immunol. 9:7442018. View Article : Google Scholar
11	Kurze AK, Buhs S, Eggert D, Oliveira-Ferrer L, Muller V, Niendorf A, Wagener C and Nollau P: Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells. Cell Commun Signal. 17:1072019. View Article : Google Scholar
12	He M, Han Y, Cai C, Liu P, Chen Y, Shen H, Xu X and Zeng S: CLEC10A is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in lung adenocarcinoma. J Cell Mol Med. 25:3391–3399. 2021. View Article : Google Scholar : PubMed/NCBI
13	Zhang Z, Li J, He T and Ding J: Bioinformatics identified 17 immune genes as prognostic biomarkers for breast cancer: Application study based on artificial intelligence algorithms. Front Oncol. 10:3302020. View Article : Google Scholar
14	Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017. View Article : Google Scholar : PubMed/NCBI
15	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar
16	Nagy A, Lanczky A, Menyhart O and Gyorffy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 8:92272018. View Article : Google Scholar : PubMed/NCBI
17	Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP and Feuston BP: Random forest: A classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci. 43:1947–1958. 2003. View Article : Google Scholar
18	Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al: Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 39:782–795. 2013. View Article : Google Scholar : PubMed/NCBI
19	Shang Y, Zhang Y, Liu J, Chen L, Yang X, Zhu Z, Li D, Deng Y, Zhou Z, Lu B and Fu CG: Decreased E2F2 expression correlates with poor prognosis and immune infiltrates in patients with colorectal cancer. J Cancer. 13:653–668. 2022. View Article : Google Scholar : PubMed/NCBI
20	Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics. 35:4200–4202. 2019. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR and Sloane BF: Cabozantinib (XL184) inhibits growth and invasion of preclinical TNBC models. Clin Cancer Res. 22:923–934. 2016. View Article : Google Scholar : PubMed/NCBI
23	Lin W, Noel P, Borazanci EH, Lee J, Amini A, Han IW, Heo JS, Jameson GS, Fraser C, Steinbach M, et al: Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med. 12:802020. View Article : Google Scholar : PubMed/NCBI
24	Narayanan K, Kumar S, Padmanabhan P, Gulyas B, Wan ACA and Rajendran VM: Lineage-specific exosomes could override extracellular matrix mediated human mesenchymal stem cell differentiation. Biomaterials. 182:312–322. 2018. View Article : Google Scholar : PubMed/NCBI
25	Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, et al: Targeting YAP-Dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6:80–95. 2016. View Article : Google Scholar : PubMed/NCBI
26	Nollau P, Wolters-Eisfeld G, Mortezai N, Kurze AK, Klampe B, Debus A, Bockhorn M, Niendorf A and Wagener C: Protein domain histochemistry (PDH): Binding of the carbohydrate recognition domain (CRD) of recombinant human glycoreceptor CLEC10A (CD301) to formalin-fixed, paraffin-embedded breast cancer tissues. J Histochem Cytochem. 61:199–205. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zizzari IG, Napoletano C, Battisti F, Rahimi H, Caponnetto S, Pierelli L, Nuti M and Rughetti A: MGL Receptor and immunity: When the ligand can make the difference. J Immunol Res. 2015.4506952015.
28	Hoober JK: ASGR1 and its enigmatic relative, CLEC10A. Int J Mol Sci. 21:48182020. View Article : Google Scholar
29	Heger L, Hofer TP, Bigley V, de Vries IJM, Dalod M, Dudziak D and Ziegler-Heitbrock L: Subsets of CD1c(+) DCs: Dendritic cell versus monocyte lineage. Front Immunol. 11:5591662020. View Article : Google Scholar
30	Zelensky AN and Gready JE: The C-type lectin-like domain superfamily. FEBS J. 272:6179–6217. 2005. View Article : Google Scholar : PubMed/NCBI
31	Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, et al: Adaptive plasticity of IL-10⁺ and IL-35⁺ T_reg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 20:724–735. 2019. View Article : Google Scholar
32	Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM and Rudensky AY: Regulatory T cells exhibit distinct features in human breast cancer. Immunity. 45:1122–1134. 2016. View Article : Google Scholar : PubMed/NCBI
33	Aguilera TA and Giaccia AJ: Molecular pathways: Oncologic pathways and their role in T-cell exclusion and immune evasion-A new role for the AXL receptor tyrosine kinase. Clin Cancer Res. 23:2928–2933. 2017. View Article : Google Scholar : PubMed/NCBI
34	Kajikawa M, Ose T, Fukunaga Y, Okabe Y, Matsumoto N, Yonezawa K, Shimizu N, Kollnberger S, Kasahara M and Maenaka K: Structure of MHC class I-like MILL2 reveals heparan-sulfate binding and interdomain flexibility. Nat Commun. 9:43302018. View Article : Google Scholar : PubMed/NCBI